5-Amino-1MQ

Why it's a capsule (the molecular weight story)

Before the mechanism: the single number that explains why 5-Amino-1MQ comes as a capsule and a GLP-1 does not is molecular weight.

Lipinski’s Rule of 5 (Lipinski et al., 1997, Advanced Drug Delivery Reviews) — one of the most-cited frameworks in drug research — predicts poor oral absorption when a compound exceeds ~500 Da in molecular weight. That cutoff was reverse-engineered from the properties of drugs that were already succeeding as oral products. It’s an empirical rule of thumb, not a law of physics, but it holds up well as a first-pass filter.

• 5-Amino-1MQ: ~159 Da (cation) / ~175 Da (iodide salt). Comfortably under the cutoff. Small, membrane-permeable, textbook orally-absorbable small molecule.
• Semaglutide (a GLP-1 receptor agonist): ~4,114 Da. Roughly 8× over the ceiling. Too large and too polar to cross the gut, and gets destroyed by enzymes before it could even try. That’s why it’s delivered by injection.

The oral route for 5-Amino-1MQ isn’t a vendor convenience decision — it’s built into the chemistry.

What it is

5-Amino-1MQ is the catalog’s only oral small-molecule NNMT inhibitor. The headline framing online — “the oral fat-burning peptide that boosts NAD” — is wrong on three counts: it isn’t a peptide, it doesn’t directly burn fat, and it doesn’t boost NAD on its own so much as stop a specific leak that would otherwise drain it. Used alone, the practical effect is marginal. Stacked correctly with an NAD substrate (NAD+ / NMN / NR), it becomes one half of a coherent longevity tool.

To understand why, you need the NAD salvage pathway picture.

The NAD salvage pathway is a cycle. NAD gets used → converted to nicotinamide (NAM) → either recycled back into NAD (good) or methylated by NNMT into 1-methylnicotinamide (1-MNA) and excreted (lost from the cycle). NNMT is the methyltransferase that pulls NAM out of the salvage loop. When NNMT activity is high, you’re losing salvageable substrate; when NNMT activity is low, more NAM stays available to be recycled.

5-Amino-1MQ (full name: 5-amino-1-methylquinolinium) is a small molecule that inhibits NNMT. With NNMT inhibited, NAM stays in the loop, the salvage pathway has more substrate to work with, and NAD levels are preserved. But “preserved” only matters if there’s NAD substrate to preserve in the first place. If you’ve already depleted your NAD pool (the situation most people taking 5-Amino-1MQ are actually in), inhibiting NNMT doesn’t conjure NAD out of nothing — it just protects what little salvage capacity you have. That’s why the standalone reports underwhelm.

The second pathway leak worth knowing: CD38. CD38 is an enzyme on immune cells whose activity rises with age and inflammation; it consumes NAD directly. So the full picture of why someone has low NAD includes both NNMT (methylating NAM out of the salvage loop) and CD38 (consuming NAD itself). Plugging only the NNMT leak while CD38 is still draining the tank gives you limited benefit. This is the framing Alex (the peptide expert on one practitioner’ Enhanced Man podcast) and one practitioner arrive at independently: you have to think about the whole pathway, not one enzyme.

How it works

NNMT inhibition is the proximate mechanism [ESTABLISHED biochemistry]. NNMT uses S-adenosylmethionine (SAM) as the methyl donor to convert nicotinamide → 1-methylnicotinamide. 5-Amino-1MQ binds NNMT and reduces that conversion rate. Two downstream consequences:

1. More NAM stays available for the NAD salvage pathway → preserved NAD pool over time.
2. Less SAM gets consumed by NNMT activity → SAM stays available for other methylation reactions (DNA methylation, neurotransmitter synthesis, phosphatidylcholine production). The “save your methyl pool” angle is real but secondary in most user reports.

Why the 60-day plateau happens. Community experience converges on the pattern: 5-Amino-1MQ works at first, then plateaus around 60 days. The mechanism appears to be global enzymatic habituation rather than receptor desensitization. NNMT enzyme levels rebuild (you can’t suppress an enzyme system forever without compensatory upregulation); CD38 creeps up; the body adapts around the inhibition. The fix isn’t “more dose” — it’s cycling off, addressing the broader NAD pathway with adjuncts, and restarting at the same dose.

The senescent-cell / cancer-fuel concern: a genuine safety nuance. If NNMT is inhibited (saving NAM) but NAD substrate is insufficient and CD38 is high, the NAD that does get salvaged can preferentially get consumed by CD38-high cells, which include senescent cells and many tumor cells. Translation: under the wrong stack conditions, you can actually be feeding the very cells you don’t want to feed. This is the operational reason 5-Amino-1MQ should never be run as a standalone “longevity hack”: always in a stack that includes NAD substrate and ideally a CD38 inhibitor. The point isn’t to scare anyone off the molecule; the point is that the NAD pathway is a circuit, and tuning one node without the others has predictable failure modes.

What the research shows

NNMT inhibition is well-established at the biochemistry / cell-biology level. The pathway is mainstream metabolism; NNMT’s role in pulling NAM out of the salvage loop is textbook.

The only published pharmacokinetic study: Awosemo et al. 2021. This single paper is the entire evidentiary foundation for the “orally bioavailable” claim. There is no other published PK study on 5-Amino-1MQ.

Awosemo O, Neelakantan H, Watowich S, Ma J, Wu L, Chow DS, Liang D. Development & validation of LC-MS/MS assay for 5-amino-1-methyl quinolinium in rat plasma: Application to pharmacokinetic and oral bioavailability studies. J Pharm Biomed Anal. 2021;204:114255. PMID 34304009 / DOI 10.1016/j.jpba.2021.114255

What it found: the researchers built and validated a method to accurately measure 5-Amino-1MQ in blood, then dosed rats by IV and oral routes and tracked what showed up in circulation. Results: oral bioavailability F% = 38.4%; oral half-life 6.90 ± 1.20 hours; IV half-life 3.80 ± 1.10 hours. The authors described the compound as “well absorbed.” Oral Cmax 2,252 ng/mL.

38% oral bioavailability is a genuinely good number — plenty of approved oral drugs sit at or below that. This isn’t a compromise route. It’s a legitimate delivery path with the data behind it.

Vendor red flag — the “Kannt et al.” mis-citation. Online vendor education pages frequently cite this study incorrectly as “Kannt et al.” The correct first author is Awosemo. If a vendor cites it wrong, they’re copying someone else’s content rather than reading the source. A useful quality signal when evaluating suppliers.

Human evidence: none. No published human pharmacokinetic or clinical studies on 5-Amino-1MQ exist — confirmed by PubMed search (2026-07-16). Any vendor or source quoting a specific human bioavailability figure (e.g. “95% oral bioavailability in humans”) is marketing, not literature. Treat all dosing and efficacy claims as extrapolated from rodent data + clinical experience.

Animal data on NNMT inhibition in body composition shows benefit in adipose-tissue NAD preservation, metabolic flexibility, and fat-reduction models. The “fat-loss peptide” marketing leans heavily on this preclinical adipose work. Translation to standalone human fat loss is weak in practice — consistent with the standalone-doesn’t-work-alone pattern.

Sub-Q route: never pharmacokinetically studied for this compound. The Awosemo 2021 paper tested IV and oral only. The commonly cited “~100% bioavailability sub-Q” figure is derived from general pharmacological principles, not from any measured study of 5-Amino-1MQ specifically. There is no published sub-Q:oral dose-conversion for this compound. Adding sub-Q complexity (sterility, reconstitution, injection) to a compound specifically valued for oral convenience — with no measured bioavailability advantage — is not justified by current data.

Adjunct biology worth knowing. The broader NAD-pathway optimization toolkit has its own preclinical literature:

• Apigenin (parsley extract, purified) — CD38 inhibitor. Plugs the other major NAD leak.
• Quercetin — also has CD38-inhibition activity and is often paired with apigenin.
• EGCG (green tea extract) — has its own NNMT-inhibition activity.
• Urolithin A (e.g. Mitopure / Timeline brand) — mitophagy activator; pairs well with NAD-pool optimization on the mitochondrial-quality side.
• Japanica Sephora extract — addresses NNMT + broader methyltransferase activity.

The one practitioner synthesis. From the Enhanced Man podcast cluster: 5-Amino-1MQ alone is marginal; in stack with ~100 mg NAD+ injection the practical effect is dramatically larger. The mechanism story tracks the biochemistry cleanly — you’re plugging the NNMT leak and supplying the substrate, instead of just doing one.

Real-world protocol

The doses and schedules here are for educational and informational purposes only. 5-Amino-1MQ is sold for research use only and is not an FDA-approved drug. This is not medical advice. Consult a qualified physician before beginning any protocol.

There is no reconstitution math for the oral form — it’s a capsule or oral liquid. (If you’re sourcing the injectable SubQ research-chem version: a 5 mg vial + 1 mL bacteriostatic water gives 5,000 mcg/mL; a 500 mcg dose = 0.1 mL = 10 units on a U-100 insulin syringe.)

Oral dosing (the standard route)

Tier	Dose	Frequency	Goal
Longevity / NAD-pool maintenance	50 mg/day	Once daily OR 1–2×/week	Pathway leak-plugging; minimal subjective load
Standard / body composition support	100 mg/day	Once daily AM	Stack with NAD+ for fuller NAD-cycle effect
Aggressive / body composition	100–150 mg/day	Split AM + noon + PM	Hunter’s body-composition protocol; pair with NAD+

Injectable form (less common)

500 mcg/day SubQ. The bioavailability calculus changes (no first-pass loss) but the protocol logic — cycle, stack, don’t run standalone — is identical.

Why microdose protocols (150–600 mcg/day) don’t work — the pharmacology

A separate class of online protocols suggests microdosing 5-Amino-1MQ at 150–600 mcg/day. These doses are biologically incoherent. [established pharmacology + Holyfield 2026 calculation] The argument, walked through:

• IC50 coverage rule: for any enzyme inhibitor to do its job, blood + tissue concentration has to clear a minimum threshold to block ≥50% of the target enzyme. Below that, the drug isn’t “lightly therapeutic” — it’s not therapeutic at all.
• 5-Amino-1MQ has no published human PK data. The cleanest available structural analog is metformin — similar molecular weight, similar positive charge, similar oral bioavailability (~38% for 5-Amino-1MQ), similar half-life. Using metformin’s pharmacokinetics as the reference frame:
  • 50–150 mg/day oral ≈ 50% NNMT inhibition (the minimum-useful tier; matches the existing tiers above)
  • 400–600 mg/day ≈ near-complete inhibition (matches the allometrically-scaled mouse dose of ~400 mg/day human equivalent from Kraus 2014)
• Microdoses (150 mcg/day) are ~400× below the IC50 threshold. The lowest concentration that showed any NAD+ increase in published research was ~1,000× higher than what microdoses achieve.
• The “but microdoses preserve some NAD+” loophole doesn’t hold. Some pro-microdose protocols argue minimal NNMT inhibition is still useful for NAD+ support. The mechanism-based takedown: NMNAT (the enzyme that converts nicotinamide → NAD+) has roughly 430× higher affinity for nicotinamide than NNMT does. Under normal conditions, nicotinamide already preferentially routes toward NAD+ synthesis; NNMT only becomes a meaningful drain when massively overexpressed (i.e., in obesity-driven adipose NNMT). For NAD+ support in a lean user, direct precursors (NAD+ injectable, NMN, NR) make infinitely more sense than microdoses of an enzyme inhibitor that doesn’t reach meaningful tissue concentrations.
• Why microdose protocols dominate the market anyway: economics. A 10 mg vial at 150 mcg/day lasts ~66 days; the same vial at 5 mg/day lasts ~2 days. Subtherapeutic protocols spread expensive material across long timelines + people get modest results (placebo + foundation + variance) and the pattern perpetuates. The compound isn’t failing; the dose is.

Who is 5-Amino-1MQ actually for — the mechanism-based target population

NNMT overexpression correlates with body fat, not with aging per se. The dramatic mouse results (35% body mass reduction, 30% fat cell size reduction) came from diet-induced obese mice — animals with pathologically elevated adipose NNMT to begin with. Blocking it corrected a dysfunction that was already present. Lean individuals have baseline adipose NNMT — there’s no overexpression creating a NAD+ drain, no dysfunction for the inhibitor to correct.

The mechanism-honest read of candidate fit:

Reader profile	Right fit for 5-Amino-1MQ?	Why
Excess body fat + metabolic dysfunction (T2D, insulin resistance, obesity-driven inflammation)	Yes — at the therapeutic 50-100 mg/day tier, NOT microdose	The mechanism (block obesity-driven adipose NNMT overexpression) maps directly onto the dysfunction
Lean + metabolically healthy + longevity-optimization goal	Probably not. Direct NAD+ precursors (NAD+ / NMN / NR) make more sense	Adipose NNMT is at baseline; nothing to inhibit; NMNAT already routes nicotinamide correctly
Moderate body fat + want body-composition support	Worth trialing at the standard 100 mg/day tier, paired with the foundation	The NNMT-elevation profile starts climbing with adiposity well below clinical obesity

This means the “Longevity / NAD-pool maintenance” tier in the dose table above carries a real mechanism caveat for genuinely lean users: at baseline adipose NNMT, even 50 mg/day may not be correcting a meaningful drain. A lean longevity user is often better served by routing budget to direct NAD+ precursors (Alyve NAD+ injectable + oral NMN/NR) than to an NNMT inhibitor with no overexpression to inhibit. OHM’s honest read: surface this distinction before any customer adds 5-Amino-1MQ on a “more is more” longevity assumption.

🎯 NET-NEW (Holyfield 2026-07-15) — Exercise outperforms 5-Amino-1MQ for NNMT inhibition in healthy people: Studies cited by Holyfield show that daily exercise inhibits NNMT expression in the cell more effectively than 5-Amino-1MQ can, in metabolically healthy individuals. The mechanism story tracks: exercise activates AMPK and metabolic sensors that independently regulate NNMT expression downward, achieving the same “keep NAM in the salvage loop” effect through a different signal path. For someone who trains daily, NNMT is already running at or near the baseline a healthy person needs — there is no elevated overexpression for the inhibitor to correct. The practical upshot: if you exercise consistently, 5-Amino-1MQ is not buying you NNMT inhibition beyond what your training already provides. The compound’s value case is for the population that can’t exercise enough to generate this effect — which brings us back to the metabolic dysfunction target population above.

Cycling — the 60-day rule

Run for 60 days. Cycle off for at least 30 days. Restart at the same dose. The off-cycle window is when you address the broader NAD pathway:

• Continue NAD+ substrate (NAD+ / NMN / NR).
• Add CD38 inhibitor (apigenin, quercetin).
• Restart 5-Amino-1MQ once the enzyme rebound / CD38 rise has equilibrated.

Going longer than 60 days without a break doesn’t get you more — it just lets the body globally habituate harder. Trying to compensate with higher doses doesn’t fix the enzymatic-rebound mechanism; it just adds load with no return.

The stack — this is the actual protocol

Never run 5-Amino-1MQ standalone for serious use. The stack template:

1. NAD substrate. Either NAD+ injection (Alyve SKU, 500 mg NAD+ vial, COA 99.49%, 509 mg actual) or oral NMN / NR. This is the substrate the NNMT-protected salvage pathway needs to actually rebuild NAD.
2. CD38 inhibition. Apigenin (parsley extract, purified — fresh parsley basketfuls won’t get you there practically) or quercetin.
3. 5-Amino-1MQ. The NNMT-leak plug.
4. (Optional) Mitochondrial-quality adjunct. Urolithin A (Mitopure / Timeline brand) for mitophagy. Pairs cleanly with the NAD-pool side.

Run this as a coherent stack on the 60-day-on / 30-day-off cadence. The 5-Amino-1MQ cycles; the NAD substrate and CD38 adjuncts can run more continuously (their own dose-frequency rules apply).

Timing

Morning dosing is standard for the oral form (most users describe a mild energy / mental-clarity effect that benefits from earlier-day delivery). If splitting for body-composition work, AM + noon + early-PM avoids late-evening dosing.

Side effects & management

The practical safety profile is light at standard doses — nothing dramatic in the way the IGF-1 LR3 or MK-677 profiles have. The notable items:

Effect	Mechanism	Practical notes
Senescent-cell / cancer-cell NAD shunting	Under-substrate + high-CD38 conditions, salvaged NAD goes to CD38-high cells (incl. senescent and tumor cells)	Mitigated by stacking NAD substrate + CD38 inhibitor. Do not run standalone in anyone with cancer risk profile.
Mild GI tolerability issues	Common to many oral compounds	Take with food
60-day plateau	Global enzymatic habituation	Cycle off — don’t dose-escalate
Methylation-related symptom shifts	Reduced NNMT activity preserves methyl pool; usually positive but can be felt	Dose adjustment if needed

Contraindications:

• Active cancer or significant cancer-history risk profile — the senescent / cancer-cell NAD-shunting mechanism is the central concern, and the prudent move is to avoid running this molecule (especially standalone, but also in stack) until that concern is genuinely cleared.
• Pregnancy / breastfeeding.
• Active malignancy under treatment.

Practical management: stack correctly (never standalone), cycle on schedule, run any longevity protocol on top of the foundations (sleep, training, protein, glycemic control) rather than as a substitute for them.

Regulatory status

Not FDA-approved for any indication. Sold as a research compound. Not technically a peptide — small molecule (a methylquinolinium derivative). No WADA listing identified specifically for 5-Amino-1MQ. Possibility of NNMT-inhibitor regulatory attention rises if any pharma-grade derivative enters clinical development.

Where to buy

5-Amino-1MQ is now available from US Pure Peptides — the primary OHM vendor. Use code OHM20 for 20% off (50mg vial, ISO 17025-accredited third-party COA). Not in Alyve’s current catalog. Given that 5-Amino-1MQ genuinely doesn’t perform well alone, stack it with NAD+ from Alyve — the substrate it protects from being methylated away.

The in-catalog SKU that does the substrate half of this stack today is NAD+ — NAD+ 500 mg per vial, Freedom Diagnostics COA 99.49%, 509 mg actual content (slightly over-spec, which is the right side of the line to be on). NAD+ is the substrate 5-Amino-1MQ exists to protect from being methylated away. Run together (when 5-Amino-1MQ lands), they’re the coherent two-half stack the biochemistry calls for. In the meantime, NAD+ on its own is the in-catalog answer to “I want to optimize my NAD pool” — direct substrate replacement, no pathway-tuning dependency.

The trust angle for an NAD-pathway SKU matters specifically because the NAD+ research-chemical market has wide quality variance: the molecule is hygroscopic, degrades on exposure to heat and moisture, and the salt form (sodium vs zwitterion vs other) affects bioavailability and pharmacokinetics. Alyve’s NAD+ COA at 99.49% with the 509 mg actual content is the verified-clean tier for a category where vendor variability is the norm. That’s the floor that makes the rest of the protocol worth running.

Offer: Use coupon OHM-15 for 15% off — Alyve’s pricing is very competitive, and buying 3 vials of any given peptide in one purchase gets you over 30% off retail. (Full disclosure: OHM-15 attributes the sale to me — said plainly, as always.)

Technical & analytical reference (chemistry & QC)

Molecular identity verified against PubChem (2026-06-23). 5-Amino-1MQ is a small molecule (quaternary methylquinolinium), NOT a peptide. It’s grouped here because it appears in metabolic/fat-loss stacks alongside peptides.

Field	Value
Molecular formula	C₁₀H₁₁N₂⁺ (cation; PubChem CID 950107); C₁₀H₁₁IN₂ (iodide salt — the commercial form)
Average MW	159.21 g/mol (cation); 286.11 g/mol (iodide salt — the form actually sold)
CAS	685079-15-6 (cation registry); 42464-96-0 (iodide salt)
Class	Small-molecule (non-peptide) NNMT (nicotinamide N-methyltransferase) inhibitor; quaternary quinolinium salt
HPLC purity criterion	RP-HPLC; research-grade ≥98% by area
MS identity	ESI-MS confirms cation m/z 159.1; UV/Vis quaternary quinolinium signature; identity by ¹H-NMR
Counterion / net peptide	Iodide salt is the standard supplied form; counterion confirmed by ion chromatography. Dose calculations should account for the iodide salt mass (1 mg of iodide salt ≈ 0.56 mg cation)
Storage / reconstitution	Solid powder room-temperature desiccated; solutions −20 °C; light-protected (quinolinium chromophore is photosensitive)
Degradation / stability	Hydrolysis-resistant; photodegradation is the main concern — keep light-protected. Mechanism of action via NNMT inhibition prevents nicotinamide methylation, indirectly preserving NAD⁺ precursor pool

Primary references: Neelakantan et al. J Med Chem 2018 (PMID 29116434) — original 5-amino-1MQ NNMT-inhibitor discovery; Kraus et al. Sci Rep 2014 (PMID 25118888) — NNMT-knockdown metabolic protection; PubChem CID 950107.

Sources

1. Enhanced Man Podcast EP4 — one practitioner + Alex on 5-Amino-1MQ, NAD salvage pathway, 60-day plateau, senescent-cell / cancer-cell NAD-shunting warning, peptide-calendar rotation framework.
2. Awosemo et al. 2021 — the only published PK study on 5-Amino-1MQ. Awosemo O, Neelakantan H, Watowich S, Ma J, Wu L, Chow DS, Liang D. Development & validation of LC-MS/MS assay for 5-amino-1-methyl quinolinium in rat plasma: Application to pharmacokinetic and oral bioavailability studies. J Pharm Biomed Anal. 2021;204:114255. PMID 34304009 / DOI 10.1016/j.jpba.2021.114255 (F%=38.4%; oral t½=6.90±1.20 hr; IV t½=3.80±1.10 hr; Cmax 2,252 ng/mL; “well absorbed”)
3. NNMT biochemistry + NAD salvage pathway literature. [ESTABLISHED biochemistry]
4. CD38 / senescent-cell NAD consumption literature.
5. Anderson — NAD precursors clinical sequencing.
6. One practitioner — MOTS-c mitochondrial. (cross-link for mitochondrial-defense stacking)
7. Alyve NAD+ COA (NAD+ 500 mg vial, lot data, 99.49% purity, 509 mg actual).
8. Holyfield. “I Only Take 2 Peptides — Here’s Why | Weekly Q&A” — NNMT/NAM/NAMPT pathway mechanic; allometric-scaling 50 mg/day minimum; exercise outperforms 5AM1MQ for NNMT inhibition in healthy people (VERIFY primary citation).
9. Pruski, D. “Turns Out 5-Amino-1MQ Holds Up Just Fine as a Capsule.” Research Radar (Substack), July 16, 2026. https://derekpruski.substack.com/p/turns-out-5-amino-1mq-holds-up-just — Lipinski Rule of 5 framing; Awosemo 2021 citation (confirms correct first author; corrects “Kannt et al.” vendor mis-citation); sub-Q route never PK-studied; no human data; dosing 50–100 mg/day.

See also: NAD+, MOTS-c, Ipamorelin, CJC-1295 / Ipamorelin, BPC-157, GHK-Cu.